Business Context and Reporting Period
This Form 8-K filing by Spero Therapeutics, Inc. (SPRO) was submitted on January 7, 2025, with a report date of January 10, 2025. The filing addresses a corporate update, preliminary financial condition as of December 31, 2024, and significant governance changes triggered by an ongoing SEC investigation.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $52.9 million (unaudited) as of December 31, 2024.
- Liquidity Outlook: Management estimates existing cash, combined with earned and non-contingent development milestone payments from GSK and other non-dilutive funding, will fund operations into mid-2026.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
- Debt: No specific debt figures are disclosed in this report.
Material Changes and Events
SEC Investigation and Wells Notice
On January 9, 2025, the Company received a Wells Notice from the SEC regarding a preliminary determination to recommend a civil enforcement action. The investigation concerns public disclosures made between March 31, 2022, and May 3, 2022, regarding the cessation of commercialization of tebipenem HBr. The potential action targets the Company, former CEO and current Chairman Ankit Mahadevia, and former CFO and current CEO Satyavrat "Sath" Shukla.
Interim Leadership Changes
Pending the resolution of the investigation, the Board implemented the following changes on January 7, 2025:
- Chairman of the Board: Frank Thomas appointed as Chairman, replacing Dr. Mahadevia (who remains a director).
- CEO: Mr. Shukla placed on paid administrative leave. Esther Rajavelu (current CFO) appointed as Interim President and CEO.
- Compensation: Ms. Rajavelu will receive an additional $20,000 per month in cash compensation for her interim role.
Guidance, Risks, and Contingencies
- Financial Data Status: The $52.9 million cash estimate is preliminary, unaudited, and subject to change upon completion of the 2024 financial statements.
- Legal Risks: If the SEC authorizes an enforcement action, the Company and individuals could face injunctions, civil monetary penalties, disgorgement, or orders barring individuals from serving as officers or directors.
- Management Stance: The Company and the named individuals maintain that disclosures were appropriate and acted in good faith. They intend to vigorously defend against the matter.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-K for the year ended December 31, 2024.
- Monitor the outcome of the SEC Wells Notice process and any subsequent enforcement actions or settlements.
- Confirm the status of the GSK development milestone payments and their timing to validate the mid-2026 liquidity runway.
- Review the Interim Period Agreements (Exhibits 10.1 and 10.2) for details on executive compensation and leave terms.